Paliogiannis Panagiotis, Mangoni Arduino Aleksander, Dettori Paola, Nasrallah Gheyath K, Pintus Gianfranco, Zinellu Angelo
Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy.
Department of Clinical Pharmacology, College of Medicine and Public Health, Flinders University, Adelaide, SA, Australia.
Front Public Health. 2020 Aug 4;8:432. doi: 10.3389/fpubh.2020.00432. eCollection 2020.
Coronavirus disease 2019 (COVID-19) is a recently described infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Since late 2019, COVID-19 has rapidly spread in virtually all countries, imposing the adoption of significant lockdown and social distancing measures. The activation of the coagulation cascade is a common feature of disseminated intravascular coagulation and adverse clinical outcomes in COVID-19 patients. In this study, we conducted a meta-analysis aiming to investigate differences in serum D-dimer concentrations in patients with and without severe COVID-19 disease. An electronic search in Medline (PubMed), Scopus and Web of Science was performed with no language restrictions, and 13 articles were reporting on 1,807 patients (585, 32.4% with severe disease) were finally identified and included in the meta-analysis. The pooled results of all studies revealed that the D-dimer concentrations were significantly higher in patients with more severe COVID-19 (SMD: 0.91 mg/L; 95% CI, 0.75 to 1.07 mg/L, < 0.0001). The heterogeneity was moderate ( = 46.5%; = 0.033). Sensitivity analysis showed that the effect size was not modified when any single study was in turn removed (effect size range, 0.87 mg/L to 0.93 mg/L). The Begg's ( = 0.76) and Egger's tests ( = 0.38) showed no publication bias. In conclusion, our systematic review and meta-analysis showed that serum D-dimer concentrations in patients with severe COVID-19 are significantly higher when compared to those with non-severe forms.
2019冠状病毒病(COVID-19)是一种最近发现的由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引起的传染病。自2019年末以来,COVID-19几乎在所有国家迅速传播,迫使各国采取严格的封锁和社交距离措施。凝血级联反应的激活是COVID-19患者发生弥散性血管内凝血和不良临床结局的一个共同特征。在本研究中,我们进行了一项荟萃分析,旨在调查重症和非重症COVID-19患者血清D-二聚体浓度的差异。我们在Medline(PubMed)、Scopus和Web of Science上进行了无语言限制的电子检索,最终确定并纳入荟萃分析的13篇文章共报道了1807例患者(585例,32.4%为重症患者)。所有研究的汇总结果显示,重症COVID-19患者的D-二聚体浓度显著更高(标准化均数差:0.91 mg/L;95%置信区间,0.75至1.07 mg/L,<0.0001)。异质性为中度(I² = 46.5%;P = 0.033)。敏感性分析表明,依次剔除任何一项研究时,效应量均未改变(效应量范围为0.87 mg/L至0.93 mg/L)。Begg检验(P = 0.76)和Egger检验(P = 0.38)均未显示发表偏倚。总之,我们的系统评价和荟萃分析表明,与非重症COVID-19患者相比,重症患者的血清D-二聚体浓度显著更高。